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Introduction
The Bcl-2 protein family regulates cellular life and death decisions 
by controlling mitochondrial outer membrane (MOM) permeabi-
lization (MOMP), a key step in the intrinsic apoptotic pathway 
(Cory and Adams, 2002; Jiang and Wang, 2004; Kroemer et al., 
2007; Youle and Strasser, 2008; Chipuk et al., 2010). Current mod-
els indicate that Bax and Bak, which directly cause MOMP, are 
regulated by other family members. In particular, antiapoptotic 
proteins, such as Bcl-2, Bcl-xL, and Mcl-1, inhibit MOMP, whereas 
members of the BH3-only subfamily promote MOMP.
A previous study has suggested that BH3-only proteins 
can be further subdivided into two classes (Letai et al., 2002). 
Direct activators are thought to bind Bax or Bak directly and ini-
tiate their oligomerization (Walensky et al., 2006; Kim et al., 
2009). In contrast, sensitizers are thought to bind only to anti-
apoptotic Bcl-2 family members, thereby inhibiting neutraliza-
tion of Bax, Bak, and the direct activators. Based on a variety of 
observations, including the ability of synthetic BH3 peptides to 
trigger Bax-mediated permeabilization of isolated mitochondria   
(Letai et al., 2002) or liposomes (Kuwana et al., 2005), pull-down 
assays performed using recombinant proteins (Kim et al., 2009), 
and  studies  of  apoptosis  induction  in  cells  lacking various 
BH3-only family members (e.g., Ren et al., 2010), Bim, trun-
cated Bid (tBid; a caspase 8–generated Bid fragment), and Puma 
are classified as direct activators, whereas Bad is viewed as a 
prototypic sensitizer. The role of other BH3-only proteins, such 
as Noxa, is somewhat less clear, with some studies concluding 
that they are sensitizers (Letai et al., 2002; Kuwana et al., 
2005; Kim et al., 2006; Ren et al., 2010) and other results sug-
gesting that they are direct activators (Du et al., 2011).
Despite the central importance of Bax and Bak in apoptotic 
responses, their activation also remains incompletely understood 
(Reed, 2006; Kroemer et al., 2007; Youle and Strasser, 2008;   
Dewson and Kluck, 2009; Chipuk et al., 2010). Three distinct 
models of Bax activation have been proposed. One postulates 
that  Bax  is  intrinsically  active  unless  inhibited  by  cytosolic   
binding partners or antiapoptotic Bcl-2 family members (Willis 
et al., 2007). A second suggests that activator BH3-only pro-
teins, which have been modeled by stapled BH3 peptides, bind 
near the Bax N terminus to induce an active Bax conformation 
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family members Bax and Bak release cytochrome c   
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this  paper,  we  show  that  activator  BH3-only  proteins 
bind tightly but transiently to the Bak hydrophobic BH3-
binding groove to induce Bak oligomerization, liposome 
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indicated that the initial binding of BH3-only proteins to 
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or mitochondrial lipids, but these reagents increase the 
strength of the Bak–BH3-only protein interaction. Point 
mutations in Bak and reciprocal mutations in the BH3-
only proteins not only confirmed the identity of the inter-
acting residues at the Bak–BH3-only protein interface 
but also demonstrated specificity of complex formation 
in vitro and in a cellular context. These observations indi-
cate that transient protein–protein interactions involving 
the Bak BH3-binding groove initiate Bak oligomerization 
and activation.
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et  al.,  2006;  Berggård  et  al.,  2007),  we  observed  a  dose- 
dependent increase in the binding of Bak to immobilized Bim 
(Fig. 1 A) with a mean dissociation constant (Kd) of 260 nM 
(Fig. 1 B). Importantly, this Bim–Bak interaction occurred in 
the absence of lipids, suggesting that Bak binds directly to Bim. 
In addition, Bak bound tBid, another direct activator, but not the 
sensitizer Bad (Fig. 1, B and C). Interestingly, Bak also bound 
Noxa as detected by SPR (Fig. 1, B–D) and in vitro pull-down 
assays (Fig. 1 E).
To assess the influence of a hydrophobic environment on 
these  interactions,  we  introduced  the  zwitterionic  detergent 
CHAPS. This addition had little effect on the initial binding   
of Bak to Bim (Fig. 1 F) or Noxa (Fig. 1 G), suggesting that 
protein–protein interactions drive the initial BH3-only protein–
Bak association. CHAPS did, however, markedly slow dissocia-
tion of complexes once they formed, reducing the mean Kds of 
the Bim–Bak and Noxa–Bak complexes to 29 and 24 nM, re-
spectively  (Fig.  1  H).  Similar  effects  were  observed  with 
MOM lipids (Fig. 1 I).
Direct activator–Bak interactions involve 
the Bak BH3-binding groove
To identify the domains responsible for complex formation, 
mutations were introduced into the binding partners. Chang-
ing three hydrophobic residues of Noxa (L29, F32, and L36) 
to Glu (Noxa 3E; Fig. 2 A) or the conserved residues L29 and 
D34 to Ala (Noxa 2A) markedly diminished the Noxa–Bak 
(Walensky et al., 2006; Gavathiotis et al., 2008; Kim et al., 2009). 
A third indicates that initial binding of activator BH3-only pro-
teins to MOM lipids is followed by interaction with Bax, leading 
to Bax membrane insertion, oligomerization, and MOMP (Lovell 
et al., 2008; Montessuit et al., 2010).
It is unclear how well any of these models explains Bak 
activation. Unlike Bax, Bak is constitutively associated with 
the MOM in the absence of activator proteins (Wei et al., 2000;   
Antonsson et al., 2001). Moreover, Bak oligomerization appears 
to be triggered by interactions involving its BH3 domain and 6 
helix (Dewson et al., 2008, 2009) rather than binding of activators 
to the 1 helix as described for Bax (Gavathiotis et al., 2008).
The present study was designed to identify steps leading 
to Bak activation. In particular, we set out to assess the inter-
action of direct activators with Bak, identify the protein domains 
involved, and evaluate the role of lipid in modulating these   
interactions. Here, we demonstrate for the first time that Bak 
oligomerization, subsequent MOMP, and Bak-mediated killing 
in intact cells involve transient interactions of BH3-only pro-
teins with the Bak BH3-binding groove.
Results and discussion
Interactions between direct activators  
and Bak
Using surface plasmon resonance (SPR), a technique that exam-
ines  interactions  between  proteins  over  time  (Jason-Moller   
Figure 1.  Direct interaction of BimEL, tBid, and Noxa with Bak. (A and D) SPR (relative units [RU]) of immobilized full-length wt human BimEL (A) or Noxa (D) 
exposed to increasing concentrations of purified BakTM. (B) Kds of various BH3-only proteins and BakTM calculated from SPR assays. Error bars are ± SD 
of three independent experiments using different chips and protein preparations. (C) SPR of immobilized BakTM exposed to 200 nM purified NoxaCT, 
BadCT, or tBid. (E) Purified S peptide–Noxa was mixed with His6-Bak or GST-Bak and then recovered on S protein–agarose as described in the Materials and 
methods. The pull-downs and one-fifth of the inputs were subjected to SDS-PAGE and immunoblotting. Molecular masses are given in kilodaltons. (F and G) SPR 
of immobilized full-length wt BimEL (F) or Noxa (G) exposed to purified BakTM in buffer ± 1% CHAPS. (H) Kds in the absence or presence of CHAPS. Error bars 
are ± SD of three experiments using different protein preparations. (I) Effect of mitochondrial lipids on Noxa–Bak binding. WB, Western blot.41 BH3-only protein–Bak interactions • Dai et al.
Noxa was used for model building (Fig. 2, G–I) because its 
smaller  size  permitted  adequate  conformational  sampling,   
although both Bim and Noxa were used (Fig. 2, J and K) to con-
firm predictions of the model. The SWISS-MODEL program 
(Kiefer et al., 2009) predicted that residues 19–45 of human 
Noxa (Hijikata et al., 1990; Oda et al., 2000) adopt an -helical 
conformation.  Superimposition  of  a  Bak  monomer  (derived 
from crystal structure of the dimer; Moldoveanu et al., 2006) 
over nuclear magnetic resonance (NMR) structure of the Mcl-1 
BH3-binding groove, a known binding site for Noxa, suggested 
that Bak has a similar binding groove composed of 3 and 4 
helices (residues 81–98 and 105–120), whereas this groove is 
blocked by R88 and Y89 (Fig. 2 G) in free monomeric Bak.   
After the helical Noxa fragment was manually docked into the 
blocked Bak groove, the crude Noxa–Bak model was refined by 
interaction (Fig. 2 B), indicating that binding involves the 
Noxa BH3 domain. In addition, mutation of Bak R127, a 
conserved residue in the BH3-binding groove of all multi-
domain Bcl-2 family members (Fig. 2 C), to Ala markedly 
diminished binding to Bim (Fig. 2 D) or Noxa (see next para-
graph). In contrast, mutation of Bak R36, which corresponds 
to a residue reported to be critical for binding of activator 
peptides to Bax (Gavathiotis et al., 2008), had no effect on 
the BH3-only protein–Bak interaction (Fig. 2, E and F). These 
results suggested that BH3-only proteins bind to the Bak BH3-
binding groove.
To  further  study  the  BH3  domain–Bak  interaction,  we 
used  homology  modeling  and  multiple  molecular  dynamics 
simulations (MMDSs) to generate a model of a BH3-only pro-
tein–Bak complex, which was then validated experimentally. 
Figure 2.  BH3 domain–Bak interactions involve the Bak 
BH3-binding groove. (A) Sequence alignment of selected 
human BH3 domains. Residues marked in red are mu-
tated in NoxaCT 3E and NoxaCT 2A. (B) SPR (rela-
tive units [RU]) of immobilized BakTM exposed to 200 
nM purified NoxaCT, NoxaCT 3E, or NoxaCT 2A.   
(C) Sequence alignment of selected human BH1 domains. 
The asterisk indicates the conserved BH3-binding groove 
Arg that is critical for the function of antiapoptotic family 
members (Sattler et al., 1997). (D) SPR (relative units) of 
immobilized full-length BimEL exposed to 200 nM BakTM 
or BakTM R127A in CHAPS. (E) Alignment of Bax and 
Bak showing Bax Lys21 (asterisk) implicated in BH3 pep-
tide binding. (F) SPR of immobilized Noxa exposed to   
400 nM BakTM or BakTM R36A. (G) Top view of Bak 
structure (Moldoveanu et al., 2006) used as a starting 
point for docking the Noxa BH3 domain and performing 
MDDSs. Note the blockage of the BH3-binding groove 
by Y89
Bak and R88
Bak (red). (H) Top view of Noxa (in 
helix  model)  in  complex  with  Bak  (in  surface  model).   
(I) Top view of Bak in the bound state showing conforma-
tional changes of Y89
Bak and R88
Bak to vacate the Noxa-
binding groove with two hydrophobic holes. (J) SPR of 
immobilized Noxa exposed to 800-nM fusions of GST 
with Bak, Bak 127A, Bak G126S, Bak 93E, Bak 114E, 
Bak 93E/114E, or GST alone. (K) SPR of immobilized 
full-length BimEL exposed to 200 nM BakTM or BakTM 
G126S. In panels A, C, and E, identical residues are in-
dicated by black shading, and similar residues are shown 
by gray shading.JCB • VOLUME 194 • NUMBER 1 • 2011   42
C-terminal His6 epitope for membrane tethering, and synthetic 
BH3 peptides (Fig. 4 B). In this system, Bak-mediated lipo-
some permeabilization (monitored by release of fluoresceinated 
dextran) was enhanced by the wild-type (wt) Bim or Noxa BH3 
peptide but not the Bad or mutant Noxa BH3 peptide (Fig. 4, 
C–E), paralleling the ability of these peptides to oligomerize 
Bak  (Fig.  4  F).  Further  experiments  compared  Bak  G126S, 
which displays diminished BH3-only protein binding (Fig. 2,   
J and K) and oligomerization, with Bak G126S/N86G, which has   
a  reciprocal  mutation  that  restores  oligomerization  (Dewson   
et al., 2008). Importantly, wt Bim BH3 peptide failed to facili-
tate  membrane  permeabilization  by  either  mutant  (Fig.  4,   
G and H). Introduction of a reciprocal N160G mutation in the 
Bim BH3 domain, which enhances the binding to Bak G126S/
N86G (see next section), selectively facilitated liposome per-
meabilization by Bak G126S/N86G, which can oligomerize, 
but not wt Bak or Bak G126S (Fig. 4, G and H). Collectively, 
these results demonstrate the importance of both BH3 domain–
Bak BH3-binding groove interactions and Bak oligomerization 
in membrane permeabilization.
To further examine the function of the BH3 protein– 
induced Bak oligomers, we added Bak, Bim, and/or Noxa to 
mitochondria from Bax
/Bak
/ mouse embryonic fibroblasts 
(MEFs). Although Bak, Bim, or Noxa alone did not induce 
MOMP, Bim + Bak or Noxa + Bak did (Fig. 4 I). Because the 
BakTM used in this experiment lacks a transmembrane do-
main, these results not only provide further evidence that Bim 
and Noxa activate Bak in vitro but also suggest that tethering of 
Bak to the membrane through its C terminus is potentially dis-
pensable for MOM disruption.
Requirement of activator BH3 domain– 
Bak BH3-binding groove interactions  
for Bak-mediated killing
To evaluate BH3-only protein–Bak interactions in a cellular 
context, Bax
/Bak
/ MEFs were reconstituted with wt Bak, 
Bak G126S (not able to bind activator BH3-only proteins;   
Fig. 2, J and K), or Bak N86G/G126S (containing a reciprocal 
mutation to potentially allow Bak to oligomerize; Dewson et al., 
2008). All constructs contained the transmembrane domain to 
mimic the native protein as closely as possible. Immunoblotting 
confirmed expression of these proteins at roughly endogenous 
levels in two independent clones (Fig. 5 A). Reconstituted MEFs 
were then transiently transfected with Bim or Noxa constructs 
at 90% transfection efficiency, plated, and allowed to form 
colonies. Under conditions that resulted in equivalent expres-
sion of transfected constructs (Fig. S2 A), wtBim and wtNoxa 
had no effect on Bax
/Bak
/ MEFs. Conversely, these con-
structs diminished the colony formation of cells expressing   
wtBak (Fig. 5 B), confirming the requirement for Bak in the 
antiproliferative effects of Bim and Noxa in this system. The 
Bak G126S mutation, which markedly diminished binding to 
BH3-only proteins and membrane permeabilization (Figs. 2, 
J and K; and 4 H), abolished the cytotoxicity of both Bim and 
Noxa (Fig. 5 B). Moreover, wtBim and wtNoxa were unable to 
kill cells reconstituted with Bak N86G/G126S (Fig. 5 B), fur-
ther suggesting that direct interaction of Bim or Noxa with Bak 
72 10-ns molecular dynamics simulations (Pang, 2004), collec-
tively offering samplings for 0.72 µs (see Materials and meth-
ods; Table S1 and Table S2). In the resulting MMDS-refined 
model, Bak R88 and Y89 vacate the groove (Fig. 2 H), and the 
helical Noxa fragment binds with L29 and L36 plugged into 
two hydrophobic holes (Fig. 2 I). This model predicts that sev-
eral additional residues in the Bak BH3-binding groove interact 
with Noxa (Fig. S1), including Bak G126 (hydrogen bonding to 
Noxa N37 and Q40), I114 (van der Waals interactions with 
Noxa C25 and L29), and F93 (– interaction with Noxa F32). 
Mutation of these key residues, like mutation of R127, dimin-
ished binding of Bak to Noxa (Fig. 2 J) or Bim (Fig. 2 K), fur-
ther establishing the importance of the Bak BH3-binding groove 
in interactions with BH3-only proteins.
Direct activator–BH3-binding groove 
interactions lead to Bak oligomerization
In further experiments, size exclusion fast protein liquid chro-
matography (FPLC) was used to assess Bak oligomerization 
state. All of these experiments included CHAPS to simulate a 
lipid environment and potentially stabilize BH3-only protein–
Bak interactions (Fig. 1 H). In the absence of BH3-only pro-
teins, Bak migration was consistent with its monomer molecular 
mass of 25 kD (Fig. 3 A, top). Bad, which binds Bak poorly 
(Fig. 1), had no effect on Bak mobility (Fig. 3 A, bottom). In 
contrast, Bim, tBid, or Noxa shifted Bak to a new peak of Mr 
200,000 (Fig. 3, B–F, red boxes). This shift occurred within 
20 min (Fig. 3 D) and was evident upon prolonged incubation 
even when the Noxa/Bak ratio was 1:10 (Fig. 3 F). Although the 
BH3-only proteins were absent from this peak of Mr 200,000 
at later times (Fig. 3, B, C, E, and F, green boxes), an intermedi-
ate complex was detected at earlier times (Fig. 3 D, orange box), 
suggesting that a transient interaction between BH3-only pro-
teins and Bak leads to Bak oligomerization. Conditions that   
inhibited oligomerization, such as omission of CHAPS (not 
depicted) or dithiothreitol (Fig. 3 G, left), also allowed detec-
tion of stable complexes in pull-down assays (Figs. 1 E and 3 G, 
right). The Noxa 2A and 3E mutants with diminished Bak bind-
ing (Fig. 2 B) failed to trigger Bak oligomerization (Fig. 3 H 
and not depicted), highlighting the role of the activator BH3   
domain in Bak activation. Moreover, oligomerization was abol-
ished by the Bak R127A mutation (Fig. 3 I) but not R36A 
mutation (Fig. 3 J), demonstrating critical involvement of the 
Bak BH3-binding groove in Bak oligomerization.
Contribution of BH3 domain–Bak 
interactions to Bak-mediated  
membrane permeabilization
Immunoprecipitations performed with an antibody that recog-
nizes the N terminus of Bak in its active conformation (Griffiths 
et al., 2001) suggested that Bak had been activated by BH3-
only protein binding in vitro (Fig. 4 A). To further assess this 
issue, the ability of Bak to permeabilize membranes was ex-
amined using liposomes composed of MOM lipids (Kuwana   
et al., 2005; Pitter et al., 2008) supplemented with DGS-
nitrilotriacetic acid (NTA)-Ni (Oh et al., 2010), purified Bak 
protein  lacking  its  transmembrane  domain  but  containing  a   43 BH3-only protein–Bak interactions • Dai et al.
Implications for Bak activation
The aforementioned results presented provide new insight into 
several aspects of Bak activation. First, our observations indicate 
that interactions between BH3 domains of activator proteins and 
the Bak BH3-binding groove initiate Bak oligomerization. This 
conclusion is based on the ability of mutations in the activator 
is required for the antiproliferative effect. Importantly, however, 
introduction of a reciprocal mutation into the BH3 domain of 
either Noxa or Bim (Noxa N37G or Bim N160G) not only en-
hanced binding to Bak N86G/G126S (Fig. S2 B) and membrane 
permeabilization (Fig. 4, G and H) but also restored the cyto-
toxicity of the BH3-only proteins in a cellular context (Fig. 5 B).
Figure 3.  Bak oligomerization depends on BH3 domain–BH3-binding groove interactions. Reactions containing purified Bak (A–H), Bak R127A (I), or Bak 
R36A (J) alone or with a threefold molar excess of Bad (A), BimEL (B), tBid (C), Noxa (D, E, G, I, and J), or Noxa 2A (H) or a 1:10 molar ratio of Noxa to 
Bak (F) was incubated for 20 min (D), 24 h (F), or 1 h (other panels) at 23°C in the absence (G) or presence of DTT (all other panels) and then subjected 
to pull-down and blotting (G, right) or applied to a Superdex S200 column (other panels). Column fractions were subjected to SDS-PAGE, transferred to 
nitrocellulose, and blotted (A, B, and F) or silver stained (other panels). Arrows indicate size markers. Red boxes show oligomerized Bak. Green boxes 
show monomeric BH3-only proteins in reactions in which Bak oligomerized. The orange box shows transient intermediate complexes.JCB • VOLUME 194 • NUMBER 1 • 2011   44
they occurred and facilitated subsequent events. These results are 
again in contrast to Bax, in which BH3-only proteins are currently 
thought to interact with MOM lipids before binding Bax.
Third, the present results provide evidence that BH3-only 
protein–Bak interactions are transient. Although the possibility of a 
transient interaction has been previously suggested (Wei et al., 
2000) because of the poor recovery of activator BH3-only proteins 
with Bak from apoptotic cells, tBid, Bim, and Puma have more re-
cently been pulled down after incubation with Bax or Bak in vitro 
(Kim et al., 2009). Our observations help resolve this apparent 
contradiction. In the absence of CHAPS or DTT, Bak does 
BH3 domain or Bak BH3-binding groove to diminish binding, Bak 
oligomerization, membrane permeabilization, and cytotoxicity as 
well as the ability of reciprocal mutations in the BH3 domain of the 
activator and BH3-binding groove of Bak to restore these functions. 
These results are in contrast to Bax, in which BH3-only proteins 
reportedly bind the 1 helix to initiate oligomerization.
Second, taking advantage of the ability of SPR to assess 
association and dissociation separately, we observed that the ini-
tial association of BH3-only proteins with Bak was unaffected 
by the CHAPS or MOM lipid. Instead, these reagents strength-
ened the BH3 domain–BH3-binding groove interactions once 
Figure 4.  Bak membrane permeabilization depends on BH3 domain–BH3-binding groove interactions. (A) Purified Bak and Noxa at the indicated molar 
ratios were incubated for 1 h in the presence of CHAPS and captured using antiactive Bak Ab-1 precoupled to protein A/G–agarose. Immunoprecipitates 
and half of the inputs were blotted with an antibody against total Bak. (B) Peptides used to trigger Bak activation in vitro. Residues mutated in various 
peptides are indicated in red. (C–E) FITC–dextran 10 encapsulated in LUVs containing 5% DGS-NTA-Ni was incubated with 500 nM (C and D) or 1 µM 
(E) His6-BakCT along with 1 µM Bim BH3 peptide, 1 or 20 µM Bad BH3 peptide, or 2 µM of the indicated Noxa BH3 peptide. FITC-dextran release was 
measured as a function of time (C) or calculated at 4,000 s from three independent experiments (D and E). Error bars are means ± SD. (F) Liposomes were 
incubated with 500 nM Bak and the indicated BH3 peptide (1 µM) at 37°C for 30 min, then cross-linked with 100 µM BMH, and analyzed. (G and H) Liposomes 
were incubated with 2 µM His6-BakCT G126S or His6-BakCT N86G/G126S in the absence or presence of a 10-fold molar excess of the indicated 
Bim BH3 peptide. FITC-dextran release was measured as a function of time (G) or calculated at 4,000 s from two independent experiments (H). (I) After mito-
chondria from Bax
/Bak
/ MEFs were incubated with purified proteins for 1 h, sedimented, and washed, the supernatant and pellet were blotted for 
cytochrome c (Cyto C) and mitochondrial Hsp60. Molecular masses are given in kilodaltons. IP, immunoprecipitation; IB, immunoblot.45 BH3-only protein–Bak interactions • Dai et al.
S protein–agarose and Ni
2+-NTA-agarose from EMD. Antibodies to the 
following antigens were purchased from the indicated suppliers: Hsp60, 
Bim, Bad, and Mcl-1 from Cell Signaling Technology; cytochrome c and 
Mcl-1 from BD; Noxa from Enzo Life Sciences; active Bak (Ab-1) from 
EMD; Bax and Bak from Millipore; and actin (goat polyclonal) from Santa 
Cruz Biotechnology, Inc. Anti–S peptide antibody was raised in our 
laboratory as previously described (Hackbarth et al., 2004). BH3 peptides 
were generated by solid-phase synthesis in the Mayo Clinic Proteomics Re-
search Center.
Protein expression and purification
Human Bcl-2 family members were evaluated in this study. cDNAs encod-
ing Noxa (available from GenBank/EMBL/DDBJ under accession no.   
NM_021127) and Noxa lacking the C-terminal domain (NoxaCT; residues 
1–40) were cloned into pET29a(+) to yield constructs with an N-terminal   
S peptide epitope tag and C-terminal His6 tag. Plasmids encoding BakTM 
(GenBank accession no. BC004431; residues 1–186) in pET29b(+) and 
pGEX-4T-1 (Moldoveanu et al., 2006) were gifts from Q. Liu and K. Gehring 
(McGill University, Montreal, Canada). cDNAs encoding BimEL (Gen-
Bank accession no. AF032457), tBid (GenBank accession no. AF042083; 
residues 61–195), and Bad (GenBank accession no. AF021792) or Bad 
lacking the C-terminal domain (BadCT; residues 1–149) were cloned into 
pET29a(+) to yield constructs with N-terminal S peptide epitope tags and 
C-terminal His6 tags. Plasmids encoding Bak mutants and Noxa mutants 
were generated using site-directed mutagenesis. All plasmids were sub-
jected to automated sequencing to verify the described alteration and con-
firm that no additional mutations were present.
Plasmids were transformed into Escherichia coli BL21 by heat shock. 
After cells were grown to an optical density of 0.8, IPTG was added to   
1 mM, and incubation was continued for 24 h at 16°C (His6-Bak, GST-Bak, 
and mutants) or 3 h at 37°C (Noxa, BimEL, Bad, tBid, and mutants). Bacte-
ria were then washed and sonicated intermittently on ice in calcium- and 
magnesium-free Dulbecco’s PBS containing 1 mM PMSF (GST-tagged pro-
teins) or TS buffer (150 mM NaCl containing 10 mM Tris-HCl, pH 7.4, and 
1 mM PMSF; His6-tagged proteins). All further steps were performed at 
4°C. His6-tagged proteins were applied to Ni
2+-NTA-agarose, and columns 
were washed with 20 vol TS buffer followed by 10 vol TS buffer containing 
40 mM imidazole and then eluted with TS buffer containing 200 mM 
imidazole.  GST-tagged  proteins  were  then  incubated  with  glutathione- 
agarose for 4 h at 4°C, and beads were washed twice with 20–25 vol 
PBS  and  eluted  with  PBS  containing  20  mM  reduced  glutathione  for   
30 min at 4°C.
SPR
Proteins for SPR were further purified by FPLC on Superdex S200 (GE 
Healthcare), concentrated in a centrifugal concentrator (Centricon; Milli-
pore), dialyzed against Biacore buffer (10 mM Hepes, pH 7.4, 150 mM 
NaCl, 0.05 mM EDTA, and 0.005% [wt/vol] Polysorbate 20), and stored 
at 4°C for <48 h before use. Binding assays were performed at 25°C on a 
biosensor (Biacore 3000; Biacore) using His6-BimEL or His6-Noxa immobilized 
on a CM5 chip and Biacore buffer containing GST or GST-BakTM (wt or 
not form oligomers, and the interaction with a BH3-only protein is 
stable enough for pull-down or SPR assays (Figs. 1 and 3 G). If 
Bak is immobilized in this monomeric state, CHAPS or lipids 
strengthen this interaction with activator BH3-only proteins. When 
Bak is not immobilized, however, these strong interactions appear 
to trigger Bak oligomerization, which is accompanied by ejection 
of the activator protein from the oligomers (Fig. 3), accounting for 
previous difficulties in detecting this interaction during apoptosis   
in vivo. These observations are again in contrast to Bax, as the 
latter reportedly remains associated with activator BH3-only 
proteins upon oligomerization in vitro.
Finally, the present results provide evidence that Noxa is a 
direct Bak activator. In particular, Noxa (like Bim) binds Bak 
tightly but transiently, oligomerizes Bak in vitro, and induces 
Bak-mediated MOMP. Importantly, the cytotoxicity of Noxa in 
Bak-expressing cells is abolished by mutation of residues re-
sponsible for Noxa–Bak complexation and restored by recipro-
cal mutations in the two partners (Fig. 5). This identification of 
Noxa as a direct Bak activator provides an explanation for the 
recent observation that 30,000 Noxa molecules per cell can be 
cytotoxic even though antiapoptotic Bcl-2 binding partners are 
3- to 10-fold more abundant (Smith et al., 2011).
In summary, the present results demonstrate that the ki-
netics of BH3-only protein–Bak interactions can be studied   
using SPR in vitro, that Bak oligomerization is initiated by tran-
sient binding of an activator BH3 domain to the Bak BH3-
binding groove, that Noxa (like tBid or Bim) can serve as a Bak 
activator, and that these interactions regulate life and death in 
intact cells, as indicated by the effects of reciprocal mutations in 
Bim or Noxa and Bak. Collectively, the present observations 
suggest that Bak activation differs substantially from current 
models of Bax activation summarized in the Introduction.
Materials and methods
Materials
Reagents were obtained as follows: lipids and extruder from Avanti   
Polar Lipids, Inc., CM5 biosensor chips from GE Healthcare, Polysorbate 
20  from  Biacore  AB,  glutathione  from  Sigma-Aldrich,  bismaleimido-
hexane (BMH) and glutathione-agarose from Thermo Fisher Scientific, and   
Figure 5.  Bim- and Noxa-induced cytotoxicity depends on BH3 domain–BH3-binding groove interactions. (A) Whole-cell lysates prepared from wt MEFs, 
Bax
/Bak
/ MEFs or Bax
/Bak
/ MEFs reconstituted with the indicated Bak constructs were harvested for immunoblotting. #1 and #2 represent inde-
pendent clones. Molecular masses are given in kilodaltons. (B) MEFs were transfected with empty vector or the indicated BH3-only protein and assayed 
for colony formation. The number of colonies obtained from cells transfected with control plasmid (pSPN) was set to 100%. Error bars are means ± SD of 
three independent experiments. DKO, double knockout.JCB • VOLUME 194 • NUMBER 1 • 2011   46
Stable cell lines
Bak
/Bax
/ MEFs (Wei et al., 2001) were transfected with wtBak (nucleo-
tides 1–636) or the indicated mutant in pcDNA3.1/Hygro (Invitrogen)   
by electroporation using a square wave electroporator (BTX 830; Har-
vard Apparatus) at 260 mV for 10 ms and, 24 h later, selected with   
800 µg/ml hygromycin. Clones were isolated using cloning rings and ana-
lyzed by immunoblotting.
Clonogenic assays
After pSPN plasmid (Hackbarth et al., 2004) encoding S peptide–Noxa 
(ORF nucleotides 1–165), S peptide–BimEL (ORF nucleotides 1–597), 
or sequence-verified mutants generated by site-directed mutagenesis were 
transfected by electroporation (see previous paragraph) along with a plas-
mid encoding EGFP–histone H2B into Bak
/Bax
/ MEFs stably express-
ing wt or mutant Bak, aliquots of 300 cells were plated in replicate 60-mm 
dishes, allowed to form colonies, and stained. The transfection efficiency, 
checked by flow cytometry for EGFP 48 h after electroporation, was gener-
ally 90%.
Model preparation
The starting structure of Noxa–Bak was generated by manually docking 
a fragment of human Noxa (residues 19–45) in the -helical conforma-
tion into the Y89-blocked groove of Bak (residues 21–183) taken from 
the crystal structure of a Bak homodimer (Protein Data Bank accession no. 
2IMT; Moldoveanu et al., 2006). This placed L29
Noxa near I114
Bak and 
L118
Bak, L36
Noxa near V129
Bak and I85
Bak, and the Noxa helix atop Y89
Bak. 
For the Bak domain or the Noxa helix, all His, Glu, Asp, Arg, and Lys 
residues were treated as HIP, GLU, ASP, ARG, and LYS, respectively. Crys-
tallographically determined H2O molecules were removed before docking. 
The topology and coordinate files of the resulting Noxa–Bak complex were 
generated by the PREP, LINK, EDIT, and PARM modules of AMBER (Assisted 
Model Building with Energy Refinement) 5.0 (Pearlman et al., 1995). The 
complex was refined by energy minimization using the SANDER module 
of AMBER 5.0 with a dielectric constant of 1.0 and 500 cycles of steepest 
descent minimization (SDM) followed by 10,000 cycles of conjugate gra-
dient minimization (CGM). The docking-generated complex and average 
complex structure of cluster 6 from first-round simulations (Table S1) were 
used for first- and second-round simulations, respectively. The energy-
minimized complex was solvated with 5,897 and 6,744 TIP3P H2O molecules 
(Jorgensen et al., 1983) for the first- and second-round simulations, leading 
to systems of 20,703 and 23,244 atoms. H2O molecules were obtained 
from solvating the complex using a preequilibrated box of 216,000 TIP3P 
molecules whose hydrogen atomic charge was set to 0.4170, in which 
any H2O molecule was removed if it had an O closer than 2.2 Å or an 
H closer than 2.0 Å to any solute atom or if it was located further than   
10.0 Å along the x, y, or z axis from any solute atom.
MMDSs
The solvated complex system was energy minimized for 100 cycles of 
SDM followed by 100 cycles of CGM to remove close van der Waals con-
tacts in the system, then heated from 0 to 300 K at a rate of 10 K/ps under 
constant  temperature  and  volume,  and  finally,  simulated  independently 
with a unique seed number for initial velocities at 300 K under constant 
temperature and pressure using the PMEMD module of AMBER 8.0 (Case 
et al., 2005) with an AMBER force field (ff99SB; Hornak et al., 2006; 
Wickstrom et al., 2009). All simulations used (a) a dielectric constant of 
1.0, (b) the Berendsen coupling algorithm (Berendsen et al., 1984), (c) a 
periodic boundary condition at a constant temperature of 300 K and a 
constant pressure of 1 atmosphere with isotropic molecule-based scaling, 
(d) the Particle Mesh Ewald method to calculate long-range electrostatic in-
teractions (Darden et al., 1993), (e) a time step of 1.0 fs, (f) the SHAKE 
bond-length constraints applied to all the bonds involving the H atom, (g) 
saving the image closest to the middle of the primary box to the restart and 
trajectory files, (h) formatted restart file, and (i) default values of all other 
inputs of the PMEMD module.
Simulation analysis
Average structures were obtained as previously described (Ekström et al., 
2009). For each of the 20 (round 1) or 52 (round 2) simulations of Noxa–
Bak, 200 (round 1) or 100 (round 2) instantaneous conformations were 
saved at 5-ps (round 1) or 10-ps (round 2) intervals during the last 1-ns 
period. A total of 4,000 (round 1) or 5,200 (round 2) instantaneous con-
formations of Noxa–Bak from the 20 (round 1) or 52 (round 2) simulations 
were subjected to a cluster analysis using the average linkage algorithm 
(epsilon = 3.0 Å and root mean square on residues 111, 134, 93, and 89 
mutant) injected at 30 µl/min for 1 min. Bound protein was allowed to dis-
sociate in Biacore buffer at 30 µl/min for 10 min and then desorbed with 
2 M MgCl2. Binding kinetics were derived using BIAevaluation software 
(Biacore). Similarly, GST-BakTM on a CM5 chip was exposed to tBid, 
BadCT, or NoxaCT and its mutants. In some experiments, Biacore buffer 
contained 1% CHAPS or large unilamellar vesicles (LUVs) as indicated in 
the figure legends.
S peptide pull-down
Purified GST-BakTM or His6-BakTM and S peptide–Noxa were incu-
bated in PBS with 5 mM DTT at 23°C for 1 h and bound to S protein– 
agarose at 4°C for 12 h. After four washes with PBS, proteins eluted in 
SDS sample buffer were subjected to SDS-PAGE and immunoblotting.
Analytical gel filtration
Purified His6-Bak and BH3-only protein were mixed in CHAPS buffer 
(1% CHAPS, 1% glycerol, 150 mM NaCl, 5 mM DTT, and 20 mM 
Hepes, pH 7.5) at 23°C for 1 h. 200-µl samples were subjected to FPLC   
at 4°C on Superdex S200. 500-µl fractions were analyzed by SDS-
PAGE followed by silver staining or immunoblotting. For calibration, 
molecular markers (Sigma-Aldrich) in CHAPS buffer were run through 
the same column.
Immunoprecipitation
After purified Bak and Noxa were incubated in CHAPS buffer (1% CHAPS, 
1% glycerol, 150 mM NaCl, and 20 mM Hepes, pH 7.5) with 5 mM DTT 
at 30°C for 1 h, immunoprecipitations were performed for 1 h at 4°C using 
5 µg antiactive Bak Ab-1 that was precoupled to protein A/G–agarose 
beads using dimethyl pimelimidate. After four washes with isotonic wash 
buffer containing 1% CHAPS, bound proteins were solubilized in SDS 
sample buffer, subjected to SDS-PAGE, and probed with antibodies that 
recognize total Bak.
Preparation of FITC-dextran lipid vesicles
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine,  1-palmitoyl-2-oleoyl-sn- 
glycero-3-phosphoethanolamine, l--phosphatidyl-inositol, cardiolipin, cho-
lesterol, and 18:1 DGS-NTA-Ni at a weight ratio of 36:22:9:8:20:5 were 
dried as thin films in glass test tubes under nitrogen and then under vac-
uum for 16 h. To encapsulate FITC-labeled dextran 10 (F-d10; Invitrogen),   
50 mg lipid in 1 ml of 20-mM Hepes and 150-mM KCl, pH 7.0, buffer 
was mixed with 50 mg F-d10, sonicated, and extruded 15 times through 
a 100-nm polycarbonate membrane. Untrapped F-d10 was removed by 
gel filtration on Sephacryl S-300 HR (GE Healthcare). Phosphate was de-
termined by colorimetric assay (Abcam).
Liposome release assay
Release of F-d10 from LUVs was monitored by fluorescence dequenching 
using a fluorimetric plate reader. After purified His6-Bak ± BH3 peptide 
was added to LUVs (final lipid concentration of 10 µg/ml), 96-well plates 
were incubated at 37°C and assayed (excitation of 485 nm and emission 
of 538 nm) every 10 s. F-d10 release was quantified by the equation 
([Fsample  Fblank]/[FTriton  Fblank] × 100), in which Fsample, Fblank, and FTriton are 
fluorescence of reagent-, buffer-, and 1% Triton X-100–treated LUVs (modi-
fied from Oh et al., 2010).
Cytochrome c release
Purified His6-Noxa, His6-BimEL, and His6-Bak were dialyzed against mito-
chondria buffer (150 mM KCl, 5 mM MgCl2, 1 mM EGTA, 25 mM Hepes, 
pH 7.5) and diluted into mitochondria buffer with 5 mM DTT. Mitochondria 
purified from Bak
/Bax
/ MEFs (Goping et al., 1998) were incubated 
with proteins at 23°C for 1 h. After centrifugation at 10,000 g for 15 min, 
supernatants and pellets were analyzed by immunoblotting.
BMH cross-linking
As an alternative to FPLC, Bak oligomers were also analyzed by SDS-PAGE 
after cross-linking. In brief, 20 µM Bak in HK buffer (20 mM Hepes, 150 mM 
KCl, pH 7.4) was preincubated with 500 µM DTT for 1 h, then incubated 
for 30 min at 37°C with liposomes at a final Bak concentration of 500 nM 
with or without 1 µM synthetic BH3 peptides. BMH was then added to a   
final concentration of 100 µM (Meng et al., 2007), and cross-linking was 
allowed to proceed at 23°C for 30 min. After the reaction was stopped by 
incubation with 5 mM DTT for 15 min, samples were diluted with SDS sam-
ple buffer, heated to 65°C for 20 min, separated on 12% (wt/vol) poly-
acrylamide gels in the presence of SDS, transferred to nitrocellulose, and 
probed with anti-Bak antibodies.47 BH3-only protein–Bak interactions • Dai et al.
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